scholarly journals Age and gender differences in the impact of diabetes on the prevalence of ischemic heart disease: a population-based register study

2008 ◽  
Vol 79 (3) ◽  
pp. 497-502 ◽  
Author(s):  
Ann-Britt E. Wiréhn ◽  
Carl Johan Östgren ◽  
John M. Carstensen
Keyword(s):  
Gender Differences ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Population Based ◽  
Ischemic Heart ◽  
Register Study ◽  
Age And Gender ◽  
Age And Gender Differences ◽  
And Gender ◽  
The Impact

scholarly journals A Cross-Sectional Study To Evaluate age and Gender Related Differences in Drug Utilization in Ischemic Heart Disease at a Tertiary Care Hospital

2018 ◽  
Vol 11 (4) ◽  
pp. 1967-1974
Author(s):  
Praveen Panchaksharimath ◽  
A. N. Praveen ◽  
R. Manjunath
Keyword(s):  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Drug Utilization ◽  
Ischemic Heart ◽  
Lipid Lowering ◽  
Prescription Data ◽  
Cross Sectional ◽  
Age And Gender ◽  
Anti Platelet Therapy ◽  
And Gender

Drug utilization study is a powerful exploratory tool to evaluate the present trends of drug prescribing and appropriateness of prescription. To analyse the age and gender related differences in utilization of different classes of drugs in patients for Ischemic heart disease (IHD) management. This cross-sectional observational study was conducted from August 2017 to March 2018 in Cardiology department, PMSSY, BMC&RI, Bengaluru. The demographic, and drug prescription data of IHD patients were analyzed according to age group (18–59 years versus ≥ 60 years) and gender wise. Out of 520 patients diagnosed with IHD, 68% were male patients and 60% were aged ≥ 60 years. The most common co-morbid condition was Hypertension (66%) and was significant in patients aged ≥ 60 years (P= 0.0033). Anti-platelet drugs (100%) followed by Lipid lowering drugs (96%) were most commonly prescribed. The average number of drugs per prescription was found to be 6.44. Prescription of Dual anti-platelet therapy was found to be significant among men (<0.0001). Prescription of Diuretics (p = 0.045) and Pregabalin (p = 0.031) were significantly higher among females and Prescription of Angiotensin receptor blockers (ARBs) was significantly higher among those aged 18–59 years. Hypertension and Diabetes Mellitus were the most common co-morbidities observed with IHD. ARBs, Diuretics, Proton pump inhibitors, Anti Diabetic Agents and Pregabalin showed significant differences in the drug utilization with respect to age and gender. Dual anti-platelet therapy was observed to be significantly higher among males. This study has been registered in CTRI (CTRI/2018/05/013949).

Chronic heart failure in patients with arterial hypertension and ischemic heart disease: age and gender specifics

2020 ◽  
pp. 63-70
Author(s):  
Elena Aleksandrova ◽  
Tatiyana Shindina ◽  
Maksim Maksimov
Keyword(s):  
Heart Failure ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Arterial Hypertension ◽  
Ischemic Heart ◽  
Walk Test ◽  
Age And Gender ◽  
Men And Women ◽  
Different Types ◽  
And Gender

Studying of the prevalence of CHF in patients with arterial hypertension and ischemic heart disease, and of the specifity of CHF in patients of different sex and age. Retrospective analysis of CHF prevalence in 2048 patients, prospective study of different types of CHF in 285 patients with conduction of echocardiography and 6 min walk test. The prevalence of CHF in our group was 29 %, in men it was found 2.8 times more often than in women. 71 % of patients with CHF were older than 60 years. Significant differences were revealed in etiology of CHF in men and women, and in patients of different age. CHF with E < 45 % was diagnosed in 35.8 % of patients, men had this type of CHF 5.8 times more often than women. CHF with preserved EF was in 64.2 % of patients, the amount of women with this variant of CHF increases to 33.3 %. Purposeful examination of patients with arterial hypertension and IHD is needed for early detection of CHF.

scholarly journals Sex and Gender Differences in Ischemic Heart Disease: Endocrine Vascular Disease Approach (EVA) Study Design

2018 ◽  
Vol 13 (1) ◽  
pp. 14-25 ◽  
Author(s):  
Valeria Raparelli ◽  
◽  
Marco Proietti ◽  
Andrea Lenzi ◽  
Stefania Basili
Keyword(s):  
Gender Differences ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Vascular Disease ◽  
Ischemic Heart ◽  
Coronary Microvascular Dysfunction ◽  
Sex And Gender ◽  
Sexual Hormones ◽  
And Gender ◽  
Sex And Gender Differences

Abstract Improvements in ischemic heart disease (IHD) management have been unbalanced between sexes, with coronary microvascular dysfunction considered the likely underlying reason. The Endocrine Vascular disease Approach (EVA) is an observational study (Clinicaltrial.gov NCT02737982) aiming to assess sex and gender interactions between coronary circulation, sexual hormones, and platelet function. Consecutive patients with IHD undergoing coronary angiography will be recruited: (1) to assess sex and gender differences in angiographic reperfusion indexes; (2) to evaluate the effects of estrogen/androgen on sex-related differences in myocardial ischemia; (3) to investigate the platelet biology differences between men and women with IHD; (4) to verify sex- and gender-driven interplay between response to percutaneous coronary intervention, platelets, sex hormones, and myocardial damage at baseline and its impact on 12-month outcomes. The integration of sex and gender in this translational project on IHD will contribute to the identification of new targets for further innovative clinical interventions.

Sign in / Sign up

Export Citation Format

Share Document